AI in Medicine - curated summaries making complex issues easy to understand

We dive into the FDA 510(k) summary for iSchemaView's Rapid Aortic Measurements, an AI tool designed to evaluate aortic and iliac arteries. We explore its performance data, curious dataset discrepancies, technical limitations, and what this clearance means for health systems looking to automate vascular imaging workflows.

Key points

This episode unpacks an executive case note from The AI Institute arguing that hospital boards must approve clinical AI and its operating environment as a single, joint decision. We explore real-world lessons from the UK's AI Airlock programme, the danger of splitting product and operational risk into separate rooms, and the four-part approval gate every health leader should implement before deployment.

Key points

In this company spotlight, we break down the FDA 510(k) summary for Volta Medical's Volta AF-Xplorer II, cleared in September 2025. We explore how this AI tool uses deep learning to help electrophysiologists annotate 3D heart maps by analyzing intracardiac signals. Listeners will learn about its hardware requirements, catheter compatibility, algorithm updates, and the bench testing data that secured its substantial equivalence clearance.

Key points

The OECD's 2026 report outlines how healthcare can move AI from isolated pilot projects to enterprise-scale deployment. Listeners will learn the critical data, governance, and workforce strategies needed to overcome bottlenecks and safely scale AI across health systems.

Key points

In this Company Spotlight, we explore the FDA 510(k) summary for Sonio Suspect, an AI tool designed to detect abnormal fetal ultrasound findings. We unpack how Sonio transitioned their algorithm from a cloud-based web application to an integrated, on-device solution, examining the performance data, the exact anatomical anomalies it screens for, and what this regulatory shift means for medtech developers and clinicians.

Key points

NICE recently published guidance on 10 artificial intelligence technologies designed to detect or characterise colorectal polyps. While 6 tools have been conditionally recommended for NHS use, the economic and clinical real-world impact remains uncertain. We unpack what this means for gastroenterologists, the 4-year evidence generation plan, and why finding more polyps does not automatically equal preventing more cancer.

Key points

How do you evaluate a medical technology that constantly changes after deployment? Maya and Sam unpack a new report from the University of Sheffield's Decision Support Unit on how health technology assessment bodies like NICE must adapt to 'frontier AI'. They explore the nightmare of evidence decay, the hidden costs of governance, and the new requirements medtech companies will face to get AI funded.

Key points

We unpack the FDA 510(k) clearance for Anumana's WatchMate Software, a deep-learning tool that reconstructs 3D models of the left atrial appendage from standard 2D ultrasound. Discover how it stacks up against human physicians and CT scans, its clinical trial results, and the practical IT realities of deploying AI in the cath lab.

Key points

We unpack the Stanford AI Index 2026 Medicine chapter to explore why AI is acing medical exams but still struggling to translate into prospective clinical trial evidence. We dive into the massive gap between FDA clearances and randomized trials, highlight which tools like ambient scribes are genuinely scaling, and reveal why smaller models are outperforming massive systems in molecular biology.

Key points

We unpack the FDA 510(k) summary for Bunkerhill Contrast CAC, an AI tool cleared to opportunistically detect and quantify coronary artery calcium on routine contrast-enhanced chest CTs. We discuss the shift from non-contrast to contrast imaging, the pivotal performance data, and what it means for clinical workflows.

Key points

The FDA is asking the healthcare industry how to regulate generative AI medical devices. We unpack their proposed competency-based approach, which evaluates AI less like software and more like a human medical resident.

Key points

We unpack the FDA 510(k) summary for Tyto Insights for Wheeze Detection (with PCCP). Listeners will learn how this over-the-counter AI software analyzes lung sounds, the real performance numbers behind it, and exactly how the FDA's Predetermined Change Control Plan allows algorithms to be retrained post-clearance without new submissions.

Key points

The AMA just surveyed nearly 1,700 physicians on their real-world use of augmented intelligence. We unpack why professional adoption has doubled, the massive hidden wave of patient AI use, and the specific liability fears keeping doctors awake at night. Essential listening for clinical leaders and medtech product teams.

Key points

We unpack the FDA 510(k) summary for Eko Health's EFAST software, which brings transformer-based AI to the digital stethoscope. Listeners will learn how the cloud-based system analyzes heart sounds and ECGs, its real-world performance numbers for detecting structural murmurs and atrial fibrillation, and the crucial caveats regarding pediatric screening and retrospective testing.

Key points

We dive into the FDA's recent clearance of AiTiALVSD, an AI tool that predicts left ventricular systolic dysfunction from a standard 12-lead ECG. We break down the clinical validation numbers, the demographic gaps in the training data, and what this specific 510(k) clearance means for cardiology workflows.

Key points

We unpack a critical Stanford and UC Berkeley report advising California on its new Transparency in Frontier AI Act (TFAIA). Discover why current legal definitions of AI risk are dangerously narrow, how a strict focus on computing power ignores biological threats, and what new reporting thresholds could mean for healthcare and medtech developers.

Key points

NICE weighs in on 4 AI technologies designed to speed up echocardiography for heart failure diagnosis. Despite incredible claims of time savings, the agency stops short of recommending NHS funding. Maya and Sam unpack the evidence gaps, the economic models, and what AI builders need to prove before winning health-system adoption.

Key points

We unpack the FDA 510(k) summary for icobrain aria by icometrix, an AI tool cleared to help radiologists detect brain swelling and bleeding in Alzheimer's patients. We explore the clinical trial data, the significant jumps in sensitivity for spotting mild abnormalities, and what it means for the rollout of new amyloid beta-directed therapies.

Key points

MedTech Europe's position paper outlines a critical juncture for medical device regulation in the EU. We unpack their proposed amendments to the MDR and IVDR, focusing on how AI should be regulated, the fight over cybersecurity reporting, and why one in three manufacturers is deprioritising the EU for product launches.

Key points

The CDC just released a blueprint for how field epidemiology training programs should handle AI. We explore a fascinating case study where AI actually harms an outbreak investigation, and unpack the new rules for training the next generation of disease detectives to use predictive models safely.

Key points

The World Bank takes a deep dive into how artificial intelligence is actually being used in medical schools across Viet Nam. Maya and Sam unpack the massive gap between student enthusiasm and institutional readiness, the risks of informal AI adoption, and what it means for the future of clinical training globally.

Key points

We unpack the FDA clearance letter for ArteraAI Breast, a software-only device designed to predict 5- and 10-year metastasis risks from standard pathology slides. We explore the specific patient population it targets, the regulatory significance of its Predetermined Change Control Plan, and why an administrative clearance letter doesn't include performance data.

Key points

The World Economic Forum has released a new framework on how Asia is deploying AI. We explore why rapid AI adoption is failing to translate into sustained value for many organizations, and how health systems and medtech companies must redesign human roles around "direction, judgement and accountability" to fix this bottleneck.

Key points

MedTech and Pharma companies are using AI to speed up regulatory submissions, but many are finding that faster output is actually leading to more rejections. This episode unpacks a 2026 white paper from IQVIA detailing why speed-first AI fails by treating regulations like a checklist, missing crucial cross-functional inconsistencies. Listeners will learn why shifting from pure speed to patient-centric velocity—and embedding AI directly into regulatory workflows—is the only way to build defensible submissions that regulators can trust.

Key points

The FDA recently cleared TumorSight Risk, an AI software that analyzes MRI and clinical data to predict the 5- and 10-year recurrence risk for breast cancer patients. Maya and Sam unpack the 510(k) summary, exploring the algorithm's impressive negative predictive value, its retrospective validation on 2,129 patients, and what it means for the future of prognostic AI in clinical practice.

Key points

DeepHealth’s Saige-Dx recently received FDA 510(k) clearance for analyzing digital breast tomosynthesis (DBT) mammograms. We unpack the public summary to see how this AI tool uses prior screening exams to reduce false positive alerts, and break down the exact testing demographics behind the clearance.

Key points

The FDA recently cleared the Artificial Intelligence Renal Assessment AIRA Version 1 for measuring kidney volume from CT scans. We break down the device's technical workflow, its impressive clinical performance metrics, and the strict regulatory controls required for AI software in medical imaging.

Key points

This episode explores a pivotal paper on the shift from narrow AI tools to feedback-driven AI agents in oncology. We discuss how these systems orchestrate multimodal data, the current evidence from real-world and simulated studies, and what hospital leaders need to know about implementation risks and governance.

Key points

Obstructive sleep apnea affects an enormous global population, but traditional sleep studies are expensive and inaccessible. Maya and Sam unpack a new meta-analysis from the Journal of Medical Internet Research evaluating whether AI-powered photoplethysmography—the optical tech in many wearables—can accurately diagnose the condition. They explore the real-world accuracy of these models, the difference between deep learning and traditional machine learning, and what this means for the future of digital health screening.

Key points

We dive into a comprehensive systematic review examining the real-world effectiveness, safety, and workflow burden of LLM-based medical report generation. Listeners will learn why highly rated AI drafts often increase editing times, why benchmark metrics obscure clinically significant errors, and why autonomous AI is not ready to replace clinician documentation.

Key points

We unpack the FDA 510(k) summary for Galen Second Read by Ibex Medical Analytics. This episode explores how this cloud-hosted AI acts as a background safety net for pathologists, analyzing prostate biopsies initially diagnosed as benign to catch missed cancers, and what the real-world trade-offs in specificity look like.

Key points

This episode unpacks the FDA 510(k) summary for Brainomix 360 Hyperdensity, an AI tool designed to automatically flag and measure intracranial hyperdensities on CT scans. We explore its clinical workflow, its performance metrics, and a fascinating pre-approved plan that allows the algorithm to be updated without new FDA submissions.

Key points

A new World Economic Forum white paper argues that health systems are evaluating AI backward. Procurement teams buy AI for efficiency, while clinicians and patients bear the risks of unproven outcomes. Maya and Sam unpack why redefining value is the only way to win the health AI race.

Key points

Health systems are eager to adopt AI for aging populations, but does the technology actually save money? We unpack a scoping review of 40 economic evaluations to reveal why most AI tools are deemed cost-saving on paper, but often lack the real-world validation to prove it.

Key points

This episode unpacks a comprehensive review spanning ten years of AI in screening mammography. Listeners will learn why pooled accuracy figures mask deep implementation challenges, how AI is effectively reducing reading workloads by up to 44.2%, and why local calibration is far more critical than an algorithm's out-of-the-box claims.

Key points

The UK government has officially accepted all 44 recommendations from the National Commission into the Regulation of AI in Healthcare. In this episode, Maya and Sam unpack the MHRA's extensive response, detailing the shift from point-in-time software checks to continuous, lifecycle-based regulation. They explore what this means for medical device manufacturers building adaptive algorithms, how healthcare systems will manage the shifting lines of clinical liability, and the practical steps the government is taking to deploy a massive tech investment safely.

Key points

The FDA recently released a framework detailing how to use digital health technologies and AI to capture clinical trial outcomes. We explore the critical differences between verification, analytical validation, and clinical validation, and what trial sponsors must do to prove a digital measure is fit for purpose.

Key points

We unpack the FDA 510(k) summary for Aidoc's BriefCase-Triage, a cloud-based AI tool cleared in May 2026. Listeners will learn how it performs in flagging large and medium vessel occlusions, the real numbers behind its 1.09-minute notification time, and the specifics of its multicenter retrospective testing.

Key points

The European Medicines Agency has released its 2025 AI Observatory report, revealing how regulators are deploying 61 internal AI use cases to evaluate pharmaceutical submissions. Maya and Sam dive deep into the specific tools the EMA is building, the AI applications applicants are bringing to early meetings, and what this means for the future of drug development.

Key points

We unpack the FDA 510(k) clearance summary for Viz Subdural+, an AI tool designed to automatically label and measure collections in the subdural space from brain CT scans. Listeners will learn how the algorithm performed in retrospective testing, how it compares to its predicate device, and what its limitations mean for hospitals buying AI.

Key points